# FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.

> **NCT00270361** · PHASE3 · COMPLETED · sponsor: **Scios, Inc.** · enrollment: 214 (actual)

## Conditions studied

- Heart Failure, Congestive

## Interventions

- **DRUG:** nesiritide
- **DRUG:** usual long term cardiac medications
- **DRUG:** nesiritide

## Key facts

- **NCT ID:** NCT00270361
- **Lead sponsor:** Scios, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** —
- **Final completion:** 2003-01
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2011-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270361, "FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00270361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*